Thymomas and thymic carcinomas: prognostic factors and multimodal management
- PMID: 23225512
- DOI: 10.1055/s-0032-1322611
Thymomas and thymic carcinomas: prognostic factors and multimodal management
Abstract
Background: Thymomas and thymic carcinomas are rare malignant tumors. We report the experience with the resection and multimodal treatment at a single department in Central Europe in the years 2001 to 2010.
Objective: We sought to determine prognostic factors in this patient population.
Methods: A 10-year retrospective analysis of 84 resections on 72 patients for thymomas/thymic carcinomas or their recurrences was performed.
Results: Patients admitted to a single thoracic surgery center presented with Masaoka-Koga stage I (29.2%), II (43.1%), III (13.9%), and IV (13.9%). In approximately 88.9% of cases, a complete resection could be reached. Using overall survival as an outcome measure, the 5-year survival rate was 87%. Of all the cases presented, 9.7% cases showed tumor recurrence and 6.9% cases showed tumor progression. There was decreased survival rate with increasing Masaoka-Koga stage (p = 0.017) and incomplete resection (p < 0.001).
Conclusion: Completeness of resection and Masaoka-Koga stage were significant prognostic factors. Multidisciplinary treatments of patients with thymoma or thymic carcinoma result in good patient care, and global efforts with larger number of patients are needed to elucidate more about the biology, diagnosis, and treatment of these tumors.
Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database.J Thorac Oncol. 2014 Apr;9(4):541-8. doi: 10.1097/JTO.0000000000000128. J Thorac Oncol. 2014. PMID: 24736078
-
Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome.Thorac Cardiovasc Surg. 2014 Mar;62(2):161-8. doi: 10.1055/s-0033-1345303. Epub 2013 Jun 17. Thorac Cardiovasc Surg. 2014. PMID: 23775415
-
Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification.Ann Thorac Surg. 2004 Sep;78(3):992-7; discussion 997-8. doi: 10.1016/j.athoracsur.2004.03.097. Ann Thorac Surg. 2004. PMID: 15337034
-
[Thymoma and thymic carcinoma--review of literature and clinical characteristics based on the Polish Paediatric Solid Tumours Study Group experience].Med Wieku Rozwoj. 2007 Jul-Sep;11(3 Pt 2):313-8. Med Wieku Rozwoj. 2007. PMID: 18663273 Review. Polish.
-
What is the role of lymph nodal metastases and lymphadenectomy in the surgical treatment and prognosis of thymic carcinomas and carcinoids?Interact Cardiovasc Thorac Surg. 2014 Dec;19(6):1054-8. doi: 10.1093/icvts/ivu281. Epub 2014 Sep 4. Interact Cardiovasc Thorac Surg. 2014. PMID: 25193970 Review.
Cited by
-
Deciphering tissue-based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors.Mol Oncol. 2020 Apr;14(4):721-741. doi: 10.1002/1878-0261.12642. Epub 2020 Feb 6. Mol Oncol. 2020. PMID: 31967407 Free PMC article.
-
Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome.Oncotarget. 2018 Apr 24;9(31):21861-21875. doi: 10.18632/oncotarget.25076. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774108 Free PMC article.
-
Induction Strategy for Locally Advanced Thymoma.Front Oncol. 2021 Jul 22;11:704220. doi: 10.3389/fonc.2021.704220. eCollection 2021. Front Oncol. 2021. PMID: 34367988 Free PMC article. Review.
-
Non-surgical treatment of locally advanced thymic epithelial tumors-a need for multicenter trials.J Thorac Dis. 2016 Aug;8(8):1859-62. doi: 10.21037/jtd.2016.05.66. J Thorac Dis. 2016. PMID: 27620337 Free PMC article. No abstract available.
-
Prognostic CT features in patients with untreated thymic epithelial tumors.Sci Rep. 2023 Feb 19;13(1):2910. doi: 10.1038/s41598-023-30041-z. Sci Rep. 2023. PMID: 36801902 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical